Azitra Taps Microbiome For Dermatology Therapies, Including Cancer Supportive Care
Executive Summary
Emerging Company Profile: Based on its founders’ research at Yale, Azitra is developing topical therapies to treat skin dysbiosis associated with chemotherapy as well as two approaches to atopic dermatitis.
You may also be interested in...
Finance Watch: Biopharma VC Deals On Track For A Record-Breaking Year
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Bayer Harnessing Skin Microbiome In New Product Development
Bayer has teamed up with skin microbiome specialist Azitra to develop consumer health products for a host of conditions.
Finance Watch: BIO Says Proposed Foreign Investment Regulations Will Lower Investment In US Biotech
Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.